Pharmacyte Biotech Inc (OTCMKTS:PMCB) Announces Its Success In Pancreatic Cancer Therapy Study

Pharmacyte Biotech Inc (OTCMKTS:PMCB) recently announced that it has gained success at completing the study on pancreatic cancer therapy. As per the report, the clinical stage company dealing in biotechnology recently completed a study on the hand thawing syringes stability in the encapsulated Cell-in-a-Box cells. These cells will be used for treating non-metastatic, locally advanced, and inoperable pancreatic cancer (LAPC) by combining a small dose of cancer prodrug ifosfamide with the live-cell encapsulation technology of the company.

Study important to test sustain capability of cells at room temperature

The data thus obtained by the company focused on the development of specific cellular therapies for deadly cancer and diabetes through hand thawing study is considered mandatory by the FDA. According to the Chief Executive Officer of PharmaCyte, Kenneth L. Waggoner, “This is yet another important study that PharmaCyte has completed to comply with the FDA’s requirements for our planned, upcoming clinical trial in LAPC. The Cell-in-a-Box® encapsulated cells are in a frozen state before they are administered to the patient.”

He further added that the main aim of the study is to find out how long can the Cell-in-a-Box encapsulated cells can sustain at a room temperature prior to administering them on the patient having cancer without losing their ability to treat cancer after they are unfrozen.

Waggoner said that since the treatment largely depends on the viability of the live human cells that have been genetically engineered the results of the study are very important. These engineered cells produce cytochrome P450 enzyme and thus activate the prodrug ifosfamide for chemotherapy.

PharmaCyte discusses its final clinical trial design

Dr. Matthias Lohr, famed scientist from Karolinska Institute in Stockholm, Sweden recently answered a few questions related to the live-cell encapsulation technology clinical trial study. The Chairman of the Scientific Advisory Board of PharmaCyte stated that when as a team they finalize the clinical trial design, they need to consider the patients’ unmet medical need with the locally advanced pancreatic cancer which can be both inoperable and non-metastatic. It should be noted that Dr. Lohr has already served as the Principal Investigator for the earlier two clinical trials related to using Cell-in-a-Box technology for patients suffering from advanced metastatic pancreatic cancer.


« »